Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223036 | 0.76 | NOS3 (0.35) | KCNH2HRH4HRH3NPC1RAB9A | |
| SCHEMBL18123545 | 0.74 | KCNH2 (0.39) | KCNH2HRH4HRH3NPC1RAB9A | |
| SCHEMBL257319 | 0.69 | PTPN11 (0.48) | NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL2546878 | 0.69 | DYRK1A (0.48) | TDO2SMN1; SMN2MAPK1 | |
| SCHEMBL21372012 | 0.69 | TDO2 (0.43) | TDO2 | |
| SCHEMBL8313715 | 0.69 | PTPN11 (0.48) | TDO2 | |
| SCHEMBL16891613 | 0.69 | KCNH2 (0.33) | KCNH2HRH4HRH3HRH2HRH1 | |
| SCHEMBL23006577 | 0.68 | KCNH2 (0.32) | KCNH2HRH4HRH3HRH2HRH1 | |
| SCHEMBL19836262 | 0.68 | HRH3 (0.38) | KCNH2HRH4HRH3NPC1RAB9A | |
| SCHEMBL31347400 | 0.67 | ALDH1A1 (0.38) | KCNH2HRH4HRH3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-11-23 | — | — | US | disclosed |
| WO-2014100734-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334861-A1 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | TDO2 2634/4885KCNH2 3856/4885HRH4 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.